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 Purpose: To determine reasons for nonparticipation in a trial of sup-
plemental screening with magnetic resonance (MR) imag-
ing after mammography and ultrasonography (US).
 Materials and 
Methods: 
Women ( n  = 2809) at elevated risk of breast cancer were 
enrolled in the American College of Radiology Imaging 
Network 6666 US Screening Protocol at 21 institutions. 
Fourteen institutions met technical and experience re-
quirements for this institutional review board–approved, 
HIPAA-compliant substudy of supplemental screening with 
MR imaging. Those women who had completed 0-, 12-, 
and 24-month screenings with mammography combined 
with US were considered for a single contrast material–
enhanced MR examination within 8 weeks after complet-
ing the 24-month mammography-US screening. A total 
of 1593 women had complete MR substudy registration 
data: 378 of them were ineligible for the study, and 1215 
had analyzable data. Reasons for nonparticipation were 
determined. Demographic data were compared between 
study participants and nonparticipants.
 Results: Of 1215 women with analyzable data, 703 (57.9%), with 
a mean age of 54.8 years, were enrolled in the MR sub-
study and 512 (42.1%) declined participation. Women 
with a 25% or greater lifetime risk of breast cancer were 
more likely to participate (odds ratio, 1.53; 95% confi -
dence interval: 1.10, 2.12). Of 512 nonparticipants, 130 
(25.4%) refused owing to claustrophobia; 93 (18.2%), 
owing to time constraints; 62 (12.1%), owing to fi nan-
cial concerns; 47 (9.2%), because their physician would 
not provide a referral and/or did not believe MR imaging 
was indicated; 40 (7.8%), because they were not inter-
ested; 39 (7.6%), because they were medically intolerant 
to MR imaging; 29 (5.7%), because they did not want to 
undergo intravenous injection; 27 (5.3%), owing to addi-
tional biopsy or other procedures that might be required 
subsequently; 21 (4.1%), owing to MR imaging schedul-
ing constraints; 11 (2.2%), because of the travel required; 
seven (1.4%), owing to gadolinium-related risks or aller-
gies; and six (1.2%), for unknown reasons.
 Conclusion: Of 1215 women with elevated breast cancer risk who could, 
according to protocol guidelines, undergo breast MR imag-
ing, only 57.9% agreed to participate.
 q RSNA, 2010
80 radiology.rsna.org n Radiology: Volume 254: Number 1—January  2010
 BREAST IMAGING: Elevated Breast Cancer Risk and Refusal for MR Screening Berg et al
round (24-month) of annual screening 
with mammography and US. The origi-
nal ACRIN 6666 Protocol and the MR 
imaging substudy had been approved by 
the Cancer Therapy Experimental Proto-
cols Committee of the National Cancer 
Institute, ACRIN, and the site institu-
tional review boards. Study and patient 
consent protocols were Health Insur-
ance Portability and Accountability Act 
compliant. Women were approached for 
participation from August 1, 2006, through 
April 21, 2008. 
 At most participating centers, women 
were told that their insurance provider 
would be billed (if their physician agreed 
to provide a referral) and that ACRIN 
study funding would cover any costs for 
MR imaging that were not covered by in-
surance. For the Canadian and Argentine 
sites, at which there was neither insur-
ance nor governmental coverage for MR 
imaging screening, ACRIN contracted to 
pay $500 for each MR screening exami-
nation. For two American sites, hospital 
or university guidelines prohibited insur-
ance billing for any examination that was 
part of a research protocol, and ACRIN 
contracted to pay these sites a maximum 
of $500 per MR screening examination. 
The amount of $500 was derived from 
actual costs and had been used in prior 
ACRIN protocols. Participants were 
supplemental breast US screening in 
women with elevated risk of breast can-
cer and at least heterogeneously dense 
breasts ( 5 ). A total of 2809 women 
were enrolled in the main study, and all 
of them met the criteria for at least in-
termediate risk ( 6 ), although the defi ni-
tions of risk were slightly different from 
those of the ACS ( 3 ). In the third round 
of annual screening in ACRIN 6666, eli-
gible participants were offered a single 
contrast-enhanced breast MR imaging 
screening examination. We were sur-
prised at the relatively low rates of par-
ticipation in this MR imaging substudy 
that we observed initially. Thus, the pur-
pose of this study was to determine the 
reasons for nonparticipation in a trial of 
supplemental screening with MR imaging 
after mammography combined with US. 
 Materials and Methods 
 Study sites were required to meet techni-
cal and experience requirements for the 
MR imaging substudy ( 7 ). Women invited 
to undergo MR imaging screening were 
actively enrolled participants in the origi-
nal ACRIN 6666 Protocol ( 7 ) and needed 
to have completed three rounds (at 0, 12, 
and 24 months) of annual screening with 
mammography and US before the date of 
MR imaging. Women were approached 
for participation in the MR imaging sub-
study shortly before, at the time of, or 
shortly after they had completed the third 
 Contrast material–enhanced mag-netic resonance (MR) imaging can depict many node-negative invasive 
breast cancers and ductal carcinomas in 
situ that are not seen at mammography 
or ultrasonography (US) ( 1 ). Although 
mammography remains the mainstay 
examination for breast cancer screen-
ing, it has reduced sensitivity when the 
breast parenchyma is dense ( 2 ). Women 
who are at high risk for breast cancer 
because they are known or suspected 
to have  BRCA1 or BRCA2 mutations of 
known penetrance often begin undergo-
ing screening when they are aged 25–30 
years ( 3 ), when the breast tissue is more 
often dense. Mammography is particu-
larly ineffective in depicting early breast 
cancer in  BRCA1 carriers ( 4 ). In 2007, 
the American Cancer Society (ACS) rec-
ommended annual supplemental screen-
ing with MR imaging in addition to 
mammography in high-risk women ( 3 ). 
 In women at intermediate breast 
cancer risk, supplemental screening with 
MR imaging may or may not be war-
ranted ( 3 ). This group includes women 
with a personal history of breast cancer, 
women with a history of previous lobu-
lar carcinoma in situ or atypical hyper-
plasia, women with a family history of 
intermediate risk (lifetime risk of 15%–
20%), and those with dense breasts ( 3 ). 
The use of supplemental screening US 
has been advocated among women who 
are at high risk but are unable to toler-
ate MR imaging and those who are at 
intermediate risk ( 1 ). 
 The American College of Radiology 
Imaging Network (ACRIN) 6666 Proto-
col was designed for the evaluation of 
 Implications for Patient Care 
 In prior research to evaluate tol- n
erance for breast MR imaging 
examinations, patient acceptance 
of this examination was probably 
overestimated, as the data of 
only those women who under-
went MR imaging were evalu-
ated; rates of claustrophobia in 
particular have probably been 
underestimated in prior reports. 
 Our results may help to inform  n
public health agencies that recom-
mend breast MR imaging screen-
ing in subgroups of women at 
increased risk of breast cancer, as 
there appear to be large groups of 
women in whom alternative screen-
ing strategies should be considered. 
 Advances in Knowledge 
 Of 1215 women at elevated risk  n
of breast cancer who were 
offered contrast-enhanced MR 
imaging screening, 703 (57.9%) 
agreed, and 627 (51.6%) of the 
women asked to participate actu-
ally completed the screening 
according to the study protocol. 
 Claustrophobia was the most  n
common reason (in 130 [25.4%] 






 ACRIN = American College of Radiology Imaging Network 
 ACS = American Cancer Society 
 NSF = nephrogenic systemic fi brosis 
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1593 women could be approached for 
participation in the substudy ( Figure ). 
Three hundred seventy-eight women 
were ineligible; nearly half of these pa-
tients were not eligible because they did 
not undergo the 24-month screening 
mammography and US examinations by 
the cutoff date for entry into the MR 
imaging substudy. Of the remaining 
1215 women, 703 (57.9%) agreed to 
participate and 512 (42.1%) did not. 
 Demographic information on the 
women who did and did not agree to 
participate in the MR substudy and on 
the overall population of women who 
were eligible for the main ACRIN 6666 
Protocol are detailed in  Table 1 . The 
median age of the patients in all three 
groups was the same, 55 years, with 
ages ranging from 25 to 91 years among 
the women who enrolled in the main 
protocol 2 years earlier and ages ranging 
from 26 to 87 years among the women 
who declined to enroll in the MR sub-
study. The results of the random-effects 
logistic regression model are detailed in 
 Table 2 . The Hispanic or Latino women 
enrolled in the main ACRIN 6666 Pro-
tocol tended to be less likely to partici-
pate: 96 agreed to participate, and 94 
refused, representing 13.7% of the 703 
substudy participants and 18.4% of the 
512 nonparticipants (odds ratio, 0.51 
[95% confi dence interval: 0.24, 1.10]). 
Women with the greatest lifetime risk 
(  25% risk according to Gail et al [ 8 ] or 
Claus et al [ 9 ] model) were more likely 
to participate in the MR substudy: 155 
agreed to participate, and 78 declined, 
representing 22.0% of those who 
agreed to participate versus 15.2% 
of those who did not (odds ratio, 1.53 
[95% confi dence interval: 1.10, 2.12]). 
The reasons the 512 women declined 
to participate in the MR substudy are 
detailed in  Table 3 . The most common 
reasons were claustrophobia, with 130 
(25.4%) women citing this reason for 
declining, and time constraints or other 
priorities, with 93 (18.2%) women stat-
ing that they declined for this reason. 
 Of the 703 women who initially 
agreed to participate in the MR sub-
study, nine withdrew their consent 
before undergoing the MR  examination. 
Another 46 women did not actually 
of participants in the original ACRIN 
6666 Protocol. Our statistical methods 
were primarily descriptive. Two-sample 
 t tests and  x 2 tests of association (Stata, 
version 10, Stata, College Station, Tex; 
SAS 9.1.3, SAS Institute, Cary, NC) 
were used to evaluate differences in 
various characteristics between the 
groups when necessary. However, to 
avoid reporting a large number of uni-
variate comparisons that may or may 
not have been generalizable (because 
of confounding or effect modifi cation ), 
we modeled the probability of partici-
pation as a function of these charac-
teristics in a logistic regression model. 
The following specifi c characteristics 
were evaluated: ethnicity, lifetime risk 
of breast cancer according to Gail 
et al (8) or Claus et al (9) model, 5-year 
risk of breast cancer according to Gail 
et al model, personal history of breast 
cancer, and prior mammography within 
14 months of study entry. We used a 
random-effects model for site to adjust 
for institution-to-institution variability. 
We evaluated the fi ts of these logistic 
models by examining the likelihood and 
using the C-statistic, and a best model 
was selected.  P    .05 was considered 
to indicate signifi cance. We examined 
patient participation rates over time, in-
cluding the periods before and after the 
March 28, 2007, publication of the ACS 
guidelines recommending MR imaging 
( 3 ) and the May 23, 2007, Food and 
Drug Administration announcement re-
garding the risk of NSF. 
 Results 
 Of 21 sites included in the original 
ACRIN 6666 Protocol, 14 met techni-
cal and experience requirements for 
the MR imaging substudy. Of 2725 eli-
gible participants enrolled in the main 
ACRIN 6666 Protocol, 2023 (74.2%) 
were at a site that was approved for MR 
imaging according to protocol guide-
lines. Some sites did not immediately 
meet all requirements, including institu-
tional review board approval; thus, 428 
women could not be registered for the 
MR imaging substudy. In addition, two 
women withdrew their consent prior to 
study registration. Thus, the remaining 
required to agree specifi cally to undergo 
follow-up MR imaging at 6 months; un-
dergo MR imaging–guided vacuum-
 assisted biopsy or US-guided core-needle 
biopsy (billed to insurance), if needed, 
on the basis of the MR results; and pro-
vide clinical follow-up information 11–14 
months after completing the MR screen-
ing examination. The MR examination 
was to be scheduled, when possible, 
for 7–14 days after the onset of menses 
in premenopausal women and to be 
completed within 8 weeks—and in no 
case more than 91 days—after the 24-
month screening mammographic and 
US examinations. 
 If a woman had any contraindications 
to MR imaging, this was recorded as her 
reason for not participating. These con-
traindications included pacemaker, an-
eurysm clip, or other implanted metallic 
device; lack of intravenous access; weight 
of more than 300 pounds; physical inabil-
ity to tolerate positioning in the MR im-
aging unit; and impaired renal function 
as indicated by an estimated glomerular 
fi ltration rate of less than 30 mL/min/
1.73 m 2 and/or a dialysis regimen (in-
dicating a risk for nephrogenic systemic 
fi brosis [NSF]). Midway through the 
study recruitment period, on May 23, 
2007, the Food and Drug Administra-
tion requested manufacturers to include 
a black box warning for all gadolinium-
based contrast agents. This information, 
including disclosure of the risk of death, 
was immediately added to the consent 
forms for this study. Claustrophobia that 
could not be controlled with sedative or 
anxiolytic premedication under the phy-
sician’s orders was recorded separately. 
 Statistical Analyses 
 If the patient was eligible for but did not 
participate in the MR imaging substudy, 
the primary reason for nonparticipation 
was recorded after the patient was in-
terviewed by the site research assistant 
and summarized on a form listing the 
possible reasons. “Other” comments 
were used if the response did not fi t 
any existing category; these comments 
were later reviewed, and additional cat-
egories were created as needed. The 
demographic data on the MR substudy 
participants were compared with those 
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Table 1
Comparison of Demographic Data among Women in Main ACRIN 6666 Protocol and 
Those Who Agreed and Declined to Undergo Breast MR Screening
Characteristic
Enrolled in and 
Eligible for Main Study 
(n = 2725)
Agreed to Enroll 
in MR Substudy 
(n = 703)*
Declined to Enroll 
in MR Substudy 
(n = 512)*
Age at enrollment (y)
 Median† 55 (25–91) 55 (25–85) 55 (26–87)
 Mean‡ 55.14 (10.1) 54.76 (9.5) 55.54 (10.2)
Race or ethnicity
 White 2519 (92.44) 659 (93.74) 472 (92.2)
 Hispanic or Latino§ 274 (10.06) 96 (13.66) 94 (18.36)
 Black or African American 100 (3.67) 17 (2.42) 11 (2.15)
 Native Hawaiian or other Pacifi c islander 4 (0.15) 1 (0.14) 2 (0.39)
 Asian 95 (3.49) 24 (3.41) 24 (4.69)
 American Indian or Native Alaskan 4 (0.15) 1 (0.14) 0
 Unknown 11 (0.40) 1 (0.14) 4 (0.78)
Menopausal status
 Premenopausal 629 (23.08) 176 (25.04) 109 (21.29)
 Perimenopausal 188 (6.90) 45 (6.40) 43 (8.40)
 Postmenopausal 1387 (50.90) 361 (51.35) 280 (54.69)
 Surgical menopause (hysterectomy) 492 (18.06) 120 (17.07) 77 (15.04)
 Data missing 29 (1.06) 1 (0.14) 3 (0.59)
Primary eligible risk factor(s)||
 Personal history of breast cancer 1443 (52.95) 320 (45.52) 262 (51.17)
 25% Lifetime risk (Gail or Claus model) 518 (19.01) 155 (22.05) 78 (15.23)
 2.5% 5-Year risk (Gail model) 411 (15.08) 128 (18.21) 98 (19.14)
 1.7% 5-Year risk (Gail model), extremely 
   dense breasts
230 (8.44) 77 (10.95) 59 (11.52)
 ADH, ALH, LCIS, or atypical papilloma 82 (3.01) 18 (2.56) 11 (2.15)
  BRCA1 or BRCA2 mutation 24 (0.88) 3 (0.43) 3 (0.59)
 History of prior chest, mediastinal, and/or 
   axillary irradiation
8 (0.29) 2 (0.28) 0
 Reason for eligibility unknown 9 (0.33) 0 1 (0.20)
Imaging history
 Time of mammography before study 
   entry (mo)#
  ,14 1979 (72.62) 492 (69.99) 379 (74.02)
  14–24 586 (21.50) 178 (25.32) 108 (21.09)
  .24 107 (3.93) 27 (3.84) 17 (3.32)
  No prior mammogram 53 (1.94) 6 (0.85) 8 (1.56)
 Prior breast US
  Reported by participant 1891 (69.39) 486 (69.13) 341 (66.60)
  Images available in year 1 
   (reported by physician)
1054 (38.68) 257 (36.56) 184 (35.94)
  Targeted 550 (20.18) 102 (14.51) 74 (14.45)
  Whole breast 540 (19.82) 164 (23.33) 121 (23.63)
 Contrast-enhanced breast MR imaging 196 (7.19) 48 (6.83) 27 (5.27)
Hormone use**
 Current HRT 148 (5.43) 40 (5.69) 40 (7.81)
 Any prior HRT 792 (29.06) 196 (27.88) 134 (26.17)
 No HRT 1785 (65.50) 467 (66.43) 338 (66.02)
Chemotherapeutic prevention 
   at study entry
 Tamoxifen 338 (12.40) 76 (10.81) 62 (12.11)
 Raloxifene 95 (3.49) 22 (3.13) 14 (2.73)
undergo MR imaging because they 
changed their mind or did not present 
for the appointment ( n = 18), they 
encountered problems with scheduling 
the MR examination ( n = 16), they had 
fi nancial concerns ( n = 7), their physi-
cian would not provide a referral ( n = 
3), or the distance to travel for the MR 
examination was prohibitive ( n = 2). 
Among the remaining 648 participants 
who were actually placed in the MR 
unit, 13 (2.0%) were unable to toler-
ate the examination, and for three of 
these women, this was owing to claus-
trophobia ( Table 3 ). For another seven 
participants, the resultant MR images 
were deemed unreadable and the patient 
refused to repeat the examination. For 
one patient, MR imaging was completed 
more than 91 days after the 24-month 
mammography and US examinations. As 
such, 627 women—51.6% of the 1215 
eligible women asked to participate—
successfully completed the MR screen-
ing examination within the specifi ed 
period. Participation rates varied by site 
and ranged from 29% to 81% among 
the sites that were active for more than 
1 year. At one site, which became quali-
fi ed to offer MR imaging during the last 
2 months of study enrollment, only two 
(8%) of 24 women asked to participate 
were able to enroll in the study. 
 Among the 627 women who com-
pleted the MR imaging examination, 
the examinations for 238 (38%) of them 
were paid for completely by ACRIN 
without billing insurance. For the other 
389 women, insurance was initially 
billed, resulting in no (n = 63) or partial 
(n = 124) payment. 
 When we evaluated the reasons for 
refusing to participate in the MR sub-
study cited before and after publication 
of the ACS recommendations for MR 
imaging screening—and the surround-
ing publicity—among the women at high 
risk for breast cancer ( 3 ), we noted a 
decrease in the rate of physicians not 
providing referrals or not believing MR 
imaging was indicated: from 20 (13.7%) 
of 146 cases before the ACS recommen-
dations to 27 (7.4%) of 366 cases af-
ter March 28, 2007 ( P = .03). However, 
the rates of reported claustrophobia 
increased over time: from 28 (19.2%) of Table 1 (continues)
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146 cases to 102 (27.9%) of 366 cases 
( P = .04). Other rates did not change 
signifi cantly over time. Revision of the 
consent form in late May 2007 to include 
information regarding the risk of death 
from NSF did not signifi cantly affect the 
rate of refusals due to concerns about 
gadolinium reactions (three of 199 cases 
on or before May 23, 2007, and four of 
313 cases after this date [ P = .83]). 
 Discussion 
 For a screening test to be practical, 
it must be widespread, well tolerated, 
and cost-effective. Breast MR imag-
ing screening is increasingly becoming 
available and being used in the United 
States and Western Europe but is less 
available in Canada and much less 
available in South America and Asia. 
In  2006 in the United States, breast MR 
imaging was offered at 64% of respond-
ing practices among surveyed members 
of the Society of Breast Imaging, but 31% 
of practices with MR imaging screening 
services did not perform MR imaging–
guided breast interventional procedures 
Characteristic
Enrolled in and 
Eligible for Main Study 
(n = 2725)
Agreed to Enroll 
in MR Substudy 
(n = 703)*
Declined to Enroll 
in MR Substudy 
(n = 512)*
 Aromatase inhibitor 142 (5.21) 31 (4.41) 19 (3.71)
Brassiere cup size
 A 449 (16.48) 104 (14.79) 89 (17.38)
 B 983 (36.07) 267 (37.98) 188 (36.72)
 C 856 (31.41) 224 (31.86) 155 (30.27)
 D 312 (11.45) 75 (10.67) 59 (11.52)
 DD 91 (3.34) 25 (3.56) 13 (2.54)
 Other 34 (1.25)†† 8 (1.14) 8 (1.56)
Note.—Unless otherwise noted, data are numbers of patients, with percentages in parentheses.
* As detailed in the Figure, registration for the MR imaging substudy was completed for a total of 1215 women, 703 of whom 
agreed to participate and 512 of whom declined to participate. 
† Numbers in parentheses are ranges.
‡ Numbers in parentheses are standard deviations.
§ The 86 Hispanic or Latino participants who agreed to participate in the MR substudy and the 79 Hispanic or Latino participants 
who declined to participate were enrolled at Centro de Estudios Radiológicos Integrales de la Mamá, Buenos Aires, Argentina.
|| Some data listed for primary eligible risk factor vary slightly from those originally reported (6) because the Gail model risk had been 
reported as the eligible risk factor but should not have been calculated at all for a few participants as the woman either was younger than 
35 years or had a history of lobular carcinoma in situ (LCIS). ADH = atypical ductal hyperplasia, ALH = atypical lobular hyperplasia.
# Number of months before study entry at which mammography was performed.
** HRT = hormone replacement therapy.
†† Includes seven cases with missing brassiere cup size.
 Table 1 (continued) 
 Comparison of Demographic Data among Women in Main ACRIN 6666 Protocol and Those 
Who Agreed and Declined to Undergo Breast MR Screening 
( 10 ). In our protocol, only 14 (70%) of 20 
active ACRIN 6666 sites met the techni-
cal and experience requirements to per-
form breast MR imaging, and participa-
tion was postponed at two sites until at 
least three MR imaging–guided biopsies 
had been completed at each facility. 
 Although recent guidelines ( 3,11 ) 
recommend annual contrast-enhanced 
MR imaging in addition to mammogra-
phy in certain groups of high-risk women, 
little has been written about patient 
acceptance of breast MR imaging. The 
data that do exist are based on pre-
maturely terminated examinations or 
those that yielded poor image quality: 
Prior studies have not addressed those 
women who refuse to even attempt to 
undergo the MR examination. 
 Several factors are known to reduce 
patient acceptance of breast MR imaging 
and include claustrophobia and the re-
quirement for intravenous contrast mate-
rial. Rates of claustrophobia and anxiety 
severe enough to cause premature termi-
nation of the MR examination vary ac-
cording to the type of MR examination, 
with the highest rates seen in association 
with brain, head and neck, and upper ex-
tremity MR imaging ( 12 ). In our series, 
13 (2.0%) of 648 women who presented 
for breast MR imaging could not com-
plete the examination, and three of these 
cases—0.5% of the women who were ac-
tually placed in the MR unit—were due to 
claustrophobia, similar to the 1.3% rate 
reported by Eshed et al ( 12 ). 
 Our study provided us with the un-
usual opportunity to record  information 
regarding women who decline to under-
go breast MR examinations. The rate 
of women reporting claustrophobia as 
the reason for declining (130 [25.4%] 
of 512) was very high in our series. In 
a Netherlands MR imaging screening 
study ( 13 ), lying in the magnet bore 
was the aspect of breast MR imaging 
most frequently reported (by 21% of 
those surveyed) as rather to extremely 
 uncomfortable. Despite this, 44% of 
women in the Netherlands cohort pre-
ferred MR imaging for screening com-
pared with 14% who preferred mam-
mography. This was due in part to the 
higher percentage of women who re-
ported that they would feel “completely 
reassured” by a favorable MR imaging 
result (64.4%) compared with the per-
centage of women who reportedly would 
be completely reassured by a favorable 
mammographic result (40.1%). 
 Higher rates of claustrophobia 
have been reported among middle-
aged women compared with the rates 
reported among other demographic 
groups ( 14 ), and a correlation with 
higher education levels and higher socio-
economic status has been reported ( 15 ). 
Although hypnosis ( 16 ) and anxiolytic 
agents such as lorazepam or diazepam 
can be used effectively to reduce claus-
trophobia, they may not be generally 
accepted for screening. The rates 
of sedative or anxiolytic medication 
use were not recorded in this study; 
however, Murphy and Brunberg ( 17 ) 
reported that 14.3% of consecutive 
patients required sedation to complete 
MR imaging. In one study ( 18 ), 91% of 
surveyed respondents who underwent 
breast MR imaging for local staging or 
screening reported mild or no discom-
fort during the examination; however, 
the patients overestimated the potential 
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we observed no increase in reports of 
concern about gadolinium reactions or 
NSF as the reason for declining partici-
pation. No women who participated in 
the protocol developed NSF. 
 A good screening test has few false-
positive results: Healthy women should 
not be harmed. Rates of false-positive 
results infl uence both the costs and 
the tolerance for a screening test. With 
mammographic screening, a recall for 
additional imaging occurs for an average 
of 6%–13% of women, with biopsy per-
formed in 3%–6% of women screened 
and 19%–32% of biopsies revealing 
cancer ( 23 ). The effects of false-positive 
results on screening compliance vary, 
with increased compliance or intent to 
comply in American women ( 24,25 ), 
no difference in compliance among Eu-
ropean women, and decreased compli-
ance in Canadian women ( 24 ). 
 In terms of breast MR imaging, 
recall rates of 11%–12% have been re-
ported with the fi rst screening and have 
decreased to as low as 2%–7% with sub-
sequent screenings ( 26,27 ). In the very 
high-risk populations studied, biopsy 
has been recommended for 7%–18% of 
women on the basis of MR imaging re-
sults, and overall, 40% of these biopsies 
have revealed cancer ( 1 ). In our current 
series, 27 (5.3%) refusals—representing 
2.2% of the 1215 women approached for 
participation—were due to concern about 
additional biopsies or testing that might 
be indicated at MR imaging. This con-
cern was probably highlighted by the in-
formed consent process. Essink-Bot et al 
( 13 ) reported that 5.1% of participants 
in the Netherlands MR imaging screen-
ing cohort were “seriously worried about 
the scan result”; this worry probably 
refl ected the participants’ fear that cancer 
might be present and, to a lesser degree, 
their concern about additional procedures 
or testing that might be required. 
 The ACS guidelines recommending 
supplemental MR imaging screening in 
women at high risk for breast cancer ( 3 ) 
were widely publicized in March 2007. 
Anecdotally, we noted improved partici-
pation rates after that announcement, 
and participation in our protocol was 
more likely among those women who 
had a very high lifetime risk of breast 
tions were deemed unreadable because 
of motion artifact or failed contrast ma-
terial injection, and the seven women 
refused to repeat the examination. 
 NSF is a rare complication associ-
ated with gadolinium-based contrast 
agents. Midway through our patient 
accrual period, on May 23, 2007, the 
Food and Drug Administration requested 
manufacturers to include a black box 
warning with all gadolinium-based con-
trast agents, and the potential risks, 
including the risk of death, were imme-
diately added to the consent forms for 
this study. We required participants to 
meet accepted standards for renal func-
tion, with glomerular fi ltration rate test-
ing performed in the women older than 
60 years and in those suspected of hav-
ing decreased renal function. Although 
the publicity surrounding the Food and 
Drug Administration announcement 
could have discouraged participation in 
this protocol, after the announcement 
benefi ts of MR imaging, and this prob-
ably increased their tolerance. 
 Open-bore MR imaging causes less 
patient anxiety and claustrophobia than 
does closed-bore MR imaging ( 19–21 ), 
but the lower fi eld strength with open-
bore MR imaging (typically 0.2–1.0 T) 
often precludes optimal breast MR im-
aging owing to the reduced signal-to-
noise ratio and the lower spatial and 
temporal resolution. In one recent re-
port ( 22 ), 18 (4.5%) of 397 consecutive 
patients referred for breast MR imaging 
were unable to undergo the examina-
tion owing to claustrophobia ( n = 15) 
or body habitus ( n = 3). These women 
underwent open-bore MR imaging at 
0.2 T, and 86% sensitivity was observed 
( 22 ). Motion-induced artifacts that re-
sult in a nondiagnostic breast MR im-
aging examination are more common 
among claustrophobic patients. In our 
series, the images generated from seven 
(1.1%) of the 648 attempted examina-
Flowchart shows overall ACRIN 6666 study population, including the women 
who agreed and those who declined to undergo a single contrast-enhanced MR 
screening examination. MS = main study ACRIN 6666.
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companies. Overall, 19.01% of the main 
ACRIN 6666 population had a 25% or 
greater lifetime risk of breast cancer as 
the main risk factor according to the Gail 
et al (8) or Claus et al (9) model and 
thereby met ACS guidelines (3) for MR 
screening. Another 0.88% had a history 
of  BRCA mutation as the main risk factor, 
and 0.29% had prior chest, mediastinal, 
or axillary radiation therapy by age 30 
years and at least 8 years earlier as the 
main risk factor also meeting ACS guide-
lines (3) for MR imaging. Thus, just over 
20% of women in the main ACRIN 6666 
protocol met ACS guidelines for high-risk 
MR imaging screening ( 3 ), with the re-
maining participants meeting the criteria 
for the intermediate risk category. 
 Because the lifetime risk of breast 
cancer decreases with increasing age, 
we allowed other defi nitions of risk in 
the ACRIN 6666 Protocol. A total of 
15.08% of the participants in the main 
ACRIN 6666 Protocol had a 5-year 
breast cancer risk of at least 2.5% 
according to the Gail et al model (8); 
another 8.44% of the women had a 
5-year risk of at least 1.7% according to 
this model and extremely dense breasts. 
These defi nitions are not specifi cally ad-
dressed in the current ACS guidelines. 
Although women with a lifetime risk of 
breast cancer of at least 20% accord-
ing to the Gail et al model ( 8 ) meet the 
ACS guidelines, the ACS recommends 
against using this model to calculate 
risk because it does not include paternal 
family history or patient age at diagnosis 
and cannot be used to predict risk of 
BRCA mutation. (See online supplement 
to ACS guidelines [ 3 ].) The Claus et al 
model ( 9 ) is among the models recom-
mended by the ACS. (See online sup-
plement to ACS guidelines [ 3 ].) Other 
accepted models used to determine risk 
for the purposes of MR imaging include 
the BRCAPRO ( 28 ), Tyrer et al ( 29 ), 
and BOADICEA (Breast and Ovarian 
Analysis of Disease Incidence and Carrier 
Estimation Algorithm) ( 30,31 ) models. 
However, these models were not widely 
available at the time the original ACRIN 
6666 Protocol was designed, and each of 
these models can yield underestimations 
of risk in small families that have few rela-
tives with breast or ovarian cancer. 
received no payment or only partial pay-
ment (less than $500) from insurance, 
and ACRIN paid the balance (up to $500) 
to the site. Even when the insurance com-
pany and/or ACRIN covered payment for 
the initial MR imaging examination, addi-
tional costs to the health care system and 
the patient could result from follow-up 
MR imaging or other testing, including 
biopsy. Concerns about costs prompted 
the refusal of 12.1% of the women who 
declined to participate in our substudy. 
Uninsured women can be billed well over 
$2000 for MR imaging, which is clearly 
prohibitive for a screening test. 
 For more than half (52.95%) of the 
participants in the main ACRIN 6666 
Protocol, a personal history of breast 
cancer was the main risk factor ( 6 ) and 
3.01% of women in the main protocol 
had a history of atypical ductal or lobu-
lar hyperplasia, atypical papilloma, or 
lobular carcinoma in situ. Per the ACS 
guidelines, there remains insuffi cient evi-
dence in favor of or against supplemental 
screening with MR imaging in women 
at intermediate risk of breast cancer 
( 3 ). This guideline may have infl uenced 
referring physicians and even insurance 
cancer and met the ACS criteria for MR 
imaging screening. Use of models to 
estimate the risk of genetic mutations that 
predispose one to breast cancer remains 
largely the domain of genetic counselors. 
Primary care physicians have less expe-
rience with such calculations and there-
fore may be reluctant to recommend MR 
imaging unless it is recommended by a 
breast specialist. For 47 (9.2%) of the 
512 women who declined to participate 
in our MR substudy, the reason cited was 
that her primary care provider would not 
provide a referral or did not believe MR 
imaging screening was indicated. However, 
the frequency of this reason decreased 
after the ACS guidelines were publicized. 
Three (0.4%) of the 703 women who ini-
tially agreed to participate cancelled for 
the same reason. 
 Not all insurers cover contrast-
enhanced breast MR imaging, even for 
women at high risk. In our population of 
627 women at intermediate and high risk 
who completed an MR imaging exami-
nation, 62 % of the examinations were 
performed at sites that initially billed the 
insurance company. For 48% of examina-
tions initially billed to insurance, the site 
Table 2
Results of Random-Effects Logistic Regression Analysis to Predict Enrollment 
among Women Approached for Breast MR Screening
Variable
Adjusted OR in Main 
Effects Model*
Final Model
Adjusted OR* z Score P Value Standard Error
Covariate of interest
 Hispanic or Latino 0.51 (0.24, 1.10) 0.51 (0.24, 1.10) 21.71 .09 0.20
 25% Lifetime risk 
  (Gail or Claus model)†
1.67 (1.08, 2.60) 1.53 (1.10, 2.12) 2.54 .01 0.25
 2.5% 5-Year risk 
  (Gail model)†
1.17 (0.76, 1.81) … … … …
 Personal history of 
  breast cancer †
1.12 (0.76, 1.64) … … … …
 Prior mammography 
  within 14 months 
  of study entry
0.90 (0.68, 1.19) … … … …
Statistical parameter
 r 0.15 (0.06, 0.32) 0.15 (0.06, 0.32) … … …
 Log likelihood‡ 2788.37 2788.89 … … …
 C-statistic 0.5594 0.5560 … … …
Note.—Results pertain to 1215 women approached for breast MR imaging screening. OR = odds ratio.
* Numbers in parentheses are 95% confi dence intervals.
† Covariate represents presence or absence of condition as primary risk factor and not the actual or abbreviated risk score.
‡ P = .79 for comparison of two models at log likelihood ratio testing.
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main ACRIN 6666 Protocol may have 
felt secure with their mammography 
and US results alone or believed that 
they were “doing enough.” 
 In summary, in a population of 1215 
women at elevated risk of breast cancer 
who were offered a contrast-enhanced MR 
imaging screening examination, only 703 
(57.9%) agreed. Seventy-fi ve women—
representing 6.2% of those asked to 
participate and 10.7% of those who 
agreed to participate—did not successfully 
complete the MR examination, and one 
did not complete MR imaging within the 
specifi ed time of 91 days after mammog-
raphy and US. Thus, only 627 (51.6%) 
of the women approached for the sub-
study successfully completed MR imaging 
screening according to the protocol. The 
modest rate of participation was due in 
part to high rates of claustrophobia (over 
25%) among the women who declined 
participation and a lack of perceived ben-
efi t on the part of the patient and/or re-
ferring physician. Our study results sug-
gest that there may be a large group of 
women at elevated risk of breast cancer 
for whom MR imaging would not be ac-
ceptable; for these women, supplemental 
screening with combined US and mam-
mography could be considered, provided 
the woman is informed of the risk of 
false-positive results with US screen-
ing ( 6 ) and the reduced sensitivity for 
cancer detection compared with the risks 
of false-positive results and the sensitivity 
of MR imaging ( 1 ). 
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Protocol had already completed three an-
nual screenings with mammography and 
US and were probably more motivated to 
participate in the substudy than are many 
other women who undergo screening. 
Some women in the main protocol, how-
ever, may have been tired of participating 
in research protocols. 
 No set dialogue was used to discuss 
the MR examination with potential 
participants, although researchers were 
encouraged to provide summary data 
from trials that had included both MR 
imaging and US examinations, in which 
93% of cancers had been seen with 
combined screening with MR imaging 
and mammography compared to 54% 
with combined screening with mam-
mography and US ( 27,32–35 ). Despite 
these results, many participants in the 
 Inconvenience (related to time con-
straints in 93 cases and to the required 
travel in 11 cases) was a factor in the 
refusal to participate for 104 (20.3%) of 
512 women. MR imaging scheduling con-
straints were problematic for another 21 
(4.1%) women who declined participa-
tion and for 16 (2.3%) of 703 women who 
initially agreed to undergo MR imaging. 
During the patient accrual period, many 
sites began to contact women in advance of 
their scheduled 24-month mammo graphy 
and US examinations and to offer sched-
uling the MR examination for the same 
day as the 24-month procedures when 
possible. Despite these efforts, schedul-
ing MR imaging for days 7–14 after the 
onset of menses can be challenging for 
perimenopausal women with irregular 
periods. Women in the main ACRIN 6666 
Table 3
Reasons for Declining or Not Completing Contrast-enhanced Breast MR Screening 













Claustrophobia 130 (25.4) 3 (0.4) 133 (10.9)
Patient time constraints and/or other priorities 93 (18.2) NA 93 (7.7)
Financial concerns† 62 (12.1) 7 (1.0) 69 (5.7)
Physician would not provide referral or did 
 believe MR was indicated
47 (9.2) 3 (0.4) 50 (4.1)
Patient not interested or did not want to participate 40 (7.8) NA 40 (3.3)
Patient could not tolerate MR imaging‡ 39 (7.6) 10 (1.4) 49 (4.0)
Patient did not want to undergo intravenous injection 29 (5.7) NA 29 (2.4)
Patient concerned about additional biopsies or
  testing that MR results might indicate
27 (5.3) NA 27 (2.2)
MR imaging scheduling constraints 21 (4.1) 16 (2.3) 37 (3.0)
Travel-related concerns§ 11 (2.2) 2 (0.3) 13 (1.1)
Gadolinium allergy or intolerance or fear of 
 reaction, including NSF
7 (1.4) NA 7 (0.6)
Reason unknown 6 (1.2) NA 6 (0.5)
Patient did not present for appointment NA 18 (2.6) 18 (1.5)
Patient withdrew consent for MR imaging NA 9 (1.3) 9 (0.7)
Technically inadequate MR examination, with 
 patient refusal to repeat
NA 7 (1.0) 7 (0.6)
 Total|| 512/1215 (42.1) 75/703 (10.7) 587/1215 (48.3)
Note.—Data are numbers of women. NA = not applicable in given group of women.
* Only a subset of responses was available for recording reasons for not completing MR imaging among the women who 
agreed to participate in the MR imaging substudy.
† Financial concerns included those related to insurance coverage and/or the deductible.
‡ Patient could not tolerate MR imaging owing to pacemaker or other implant, body habitus, and/or frail medical condition.
§ Patient was concerned about the distance required to travel for MR examination and/or the related inconvenience, or patient moved.
|| One participant underwent MR imaging outside the time frame specifi ed for the study protocol. Thus, a total of 627 
participants successfully completed the MR screening examination according to the protocol.
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